Please login to the form below

Not currently logged in
Email:
Password:

M Booth Health appoints Karen Strauss to lead strategy and innovation

Strauss joins with expertise and experience gained at Ketchum

Karen Strauss

New York-based health communications consultancy M Booth Health has appointed Karen Strauss (pictured above) to the role of chief strategy and innovation officer.

Strauss will lead the firm’s strategic and creative planning function, while also developing new products and services to add to the company’s track-record.

She will report to M Booth Health CEO Timothy Bird, and will become one of 12 senior leaders at the consultancy, which specialises in public affairs, pharma marketing and advocacy.

Prior to joining M Booth Health, Strauss was a partner at Ketchum, most recently working in the role of executive creative director/health. Before the firm reorganised, she also served as chief global strategy and creativity officer.

Over the course of her three-decade career at Ketchum, Strauss held various leadership roles including chief innovation officer and head of both the healthcare and consumer marketing practices.

“Karen’s ability to devise imaginative, new ways to reach and inform healthcare professionals and patients, while also innovating new services to offer our clients and future clients, is an exciting development for M Booth Health,” said Bird.

Strauss is also tasked with finding synergies between M Booth Health and M Booth – although it operates as its own individual company, M Booth Health reports to M Booth CEO Dale Bornstein.

The appointment follows the recent rebranding of M Booth Health, which was formerly the US division of Health Unlimited until it was acquired by Next Fifteen Communications Group last October.

Article by
Lucy Parsons

13th February 2020

From: Marketing

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics